Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250004/S001

MMR IHC Panel pharmDx (Dako Omnis)

Agilent Technologies, Inc. · Decision date Sep 11, 2026

MEDTECHLEDGER EXPLANATIONP250004/S001

What did the FDA decide?

FDA posted an OK30 decision for supplement S001 to PMA P250004 for the MMR IHC Panel pharmDx (Dako Omnis). The supplement type is a 30-Day Notice, and the stated reason is a process change involving the manufacturer, sterilizer, packager, or supplier. The decision statement describes approval of manufacturing process and equipment changes for filling and capping.

This notice does not represent a new approval of the full immunohistochemistry test system. The source record does not state which filling or capping equipment, facility, or process parameters changed, nor does it provide safety or effectiveness data. The relationship to the original PMA is established only by the shared P250004 identifier; no clinical indication or performance conclusion can be drawn from the posted fields.

FDA approval order statement

approval of manufacturing process and equipment changes for filling and capping
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Sep 11, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250004/S001
Regulatory pathway
PMA supplement
Product code
QNH
Decision code
OK30
Decision date
Sep 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay.

Product code
QNH
FDA device class
3

For the original device and its historical approval scope, see PMA P250004. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250004 · Original PMA

    MMR IHC Panel pharmDx (Dako Omnis)

  2. P250004/S001 received

    Application receipt date recorded by FDA.

  3. P250004/S001 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P250004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250004

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA approvalAug 15, 2025FDA

Explore the linked device profile

Other records with product code QNH

Product / regulatory recordCompanyPathwayDecision dateSource
Ventana Medical SystemsPMA supplementOct 8, 2026FDA
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)PMA supplementOct 8, 2026FDA
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)PMA approvalAug 17, 2021FDA
Ventana Medical SystemsPMA approvalApr 22, 2021FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6392 Via Real, Carpinteria, CA, 93013

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records